Prostate cancer vaccine Zproxal - ZonagenAlternative Names: Zproxal
Latest Information Update: 15 Sep 2003
At a glance
- Originator Repros Therapeutics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 31 Dec 2002 Discontinued - Clinical-Phase-Unknown for Prostate cancer in Mexico (unspecified route)
- 18 Dec 2000 New profile
- 18 Dec 2000 Investigation in Prostate cancer in Mexico (Unknown route)